Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
J Mater Chem B ; 8(34): 7723-7732, 2020 09 14.
Article in English | MEDLINE | ID: mdl-32725026

ABSTRACT

Computed tomography (CT) is one of the most widespread imaging techniques in clinical use worldwide. CT contrast agents are administered to improve soft tissue contrast and highlight blood vessels. However, the range of CT contrast agents available in the clinic is limited and they suffer from short-circulation times and low k-edge values that result in the need for high doses for in vivo applications. Nanomaterials containing a mixture of electron-dense elements, such as BaYbF5 nanoparticles, have shown promise as more efficient CT contrast agents, but they require biocompatible coatings for biomedical applications. Here, we explore the use of a bifunctional PEG polymer (5 kDa) containing a terminal bisphosphonate (BP) anchor for efficient binding to the surface of BaYbF5 nanomaterials. The resulting PEG(5)-BP-BaYbF5 nanoparticles were synthesized and characterized using TEM, DLS, TGA, XRD and Z-potential measurements. Their in vitro stability was verified and their ability to produce CT contrast in a wide range of X-ray energies, covering preclinical and clinical scanners, was demonstrated. In vitro toxicity studies with PEG(5)-BP-BaYbF5 in the phagocytic pro-monocytic human cell line U937 did not identify toxic effects, even at high concentrations (30 mM). In vivo, PEG(5)-BP-BaYbF5 exhibited efficient CT contrast for angiography imaging, highlighting blood vessels and vascular organs, and long circulation times as expected from the PEG coating. However, at late time points (48 h), in vivo toxicity was observed. While the causes could not be completely elucidated, in vitro studies suggest that decomposition and release of Yb3+ and/or Ba2+ metal ions after decomposition of PEG(5)-BP-BaYbF5 may play a role. Overall, despite the promising CT contrast properties, our results suggest that BaYbF5 nanomaterials may suffer from significant long-term toxicities.


Subject(s)
Biocompatible Materials/chemistry , Biocompatible Materials/toxicity , Diphosphonates/chemistry , Nanoparticles/chemistry , Polyethylene Glycols/chemistry , Tomography, X-Ray Computed/methods , Biocompatible Materials/chemical synthesis , Cell Line, Tumor , Chemistry Techniques, Synthetic , Humans
2.
Metallomics ; 9(11): 1622-1633, 2017 11 15.
Article in English | MEDLINE | ID: mdl-29063080

ABSTRACT

Alzheimer's disease can involve brain copper dyshomeostasis. We aimed to determine the effect of AD-like pathology on 64Cu trafficking in mice, using positron emission tomography (PET imaging), during 24 hours after intravenous administration of ionic 64Cu (Cu(ii) acetate) and 64Cu-GTSM (GTSMH2 = glyoxalbis(thiosemicarbazone)). Copper trafficking was evaluated in 6-8-month-old and 13-15 month-old TASTPM transgenic and wild-type mice, by imaging 0-30 min and 24-25 h after intravenous administration of 64Cu tracer. Regional 64Cu distribution in brains was compared by ex vivo autoradiography to that of amyloid-ß plaque. 64Cu-acetate showed uptake in, and excretion through, liver and kidneys. There was minimal uptake in other tissues by 30 minutes, and little further change after 24 h. Radioactivity within brain was focussed in and around the ventricles and was significantly greater in younger mice. 64CuGTSM was taken up in all tissues by 30 min, remaining high in brain but clearing substantially from other tissues by 24 h. Distribution in brain was not localised to specific regions. TASTPM mice showed no major changes in global or regional 64Cu brain uptake compared to wildtype after administration of 64Cu acetate (unlike 64Cu-GTSM) but efflux of 64Cu from brain by 24 h was slightly greater in 6-8 month-old TASTPM mice than in wildtype controls. Changes in copper trafficking associated with Alzheimer's-like pathology after administration of ionic 64Cu are minor compared to those observed after administration of 64Cu-GTSM. PET imaging with 64Cu could help understand changes in brain copper dynamics in AD and underpin new clinical diagnostic imaging methods.


Subject(s)
Alzheimer Disease/metabolism , Copper Radioisotopes/pharmacokinetics , Disease Models, Animal , Positron-Emission Tomography/methods , Acetates/administration & dosage , Acetates/pharmacokinetics , Administration, Intravenous , Alzheimer Disease/diagnostic imaging , Animals , Biological Transport , Brain/metabolism , Coordination Complexes , Copper Radioisotopes/administration & dosage , Humans , Metabolic Clearance Rate , Mice, Transgenic , Organometallic Compounds/administration & dosage , Organometallic Compounds/pharmacokinetics , Thiosemicarbazones/administration & dosage , Thiosemicarbazones/pharmacokinetics , Tissue Distribution
3.
ACS Nano ; 10(11): 10294-10307, 2016 11 22.
Article in English | MEDLINE | ID: mdl-27781436

ABSTRACT

The clinical value of current and future nanomedicines can be improved by introducing patient selection strategies based on noninvasive sensitive whole-body imaging techniques such as positron emission tomography (PET). Thus, a broad method to radiolabel and track preformed nanomedicines such as liposomal drugs with PET radionuclides will have a wide impact in nanomedicine. Here, we introduce a simple and efficient PET radiolabeling method that exploits the metal-chelating properties of certain drugs (e.g., bisphosphonates such as alendronate and anthracyclines such as doxorubicin) and widely used ionophores to achieve excellent radiolabeling yields, purities, and stabilities with 89Zr, 52Mn, and 64Cu, and without the requirement of modification of the nanomedicine components. In a model of metastatic breast cancer, we demonstrate that this technique allows quantification of the biodistribution of a radiolabeled stealth liposomal nanomedicine containing alendronate that shows high uptake in primary tumors and metastatic organs. The versatility, efficiency, simplicity, and GMP compatibility of this method may enable submicrodosing imaging studies of liposomal nanomedicines containing chelating drugs in humans and may have clinical impact by facilitating the introduction of image-guided therapeutic strategies in current and future nanomedicine clinical studies.


Subject(s)
Copper Radioisotopes , Liposomes , Nanomedicine , Positron-Emission Tomography , Breast Neoplasms/diagnostic imaging , Female , Humans , Manganese , Radioisotopes , Tissue Distribution , Zirconium
4.
J Nucl Med ; 57(1): 109-14, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26449834

ABSTRACT

UNLABELLED: Alzheimer disease (AD) is a fatal neurodegenerative disorder characterized by progressive neuronal loss and cognitive decline. The lack of reliable and objective diagnostic markers for AD hampers early disease detection and treatment. Growing evidence supports the existence of a dysregulation in brain copper trafficking in AD. The aim of this study was to investigate brain copper trafficking in a transgenic mouse model of AD by PET imaging with (64)Cu, to determine its potential as a diagnostic biomarker of the disorder. METHODS: Brain copper trafficking was evaluated in 6- to 8-mo-old TASTPM transgenic mice and age-matched wild-type controls using the (64)Cu bis(thiosemicarbazone) complex (64)Cu-GTSM (glyoxalbis(N(4)-methyl-3-thiosemicarbazonato) copper(II)), which crosses the blood-brain barrier and releases (64)Cu bioreductively into cells. Animals were intravenously injected with (64)Cu-GTSM and imaged at 0-30 min and 24-25 h after injection. The images were analyzed by atlas-based quantification and texture analysis. Regional distribution of (64)Cu in the brain 24 h after injection was also evaluated via ex vivo autoradiography and compared with amyloid-ß plaque deposition in TASTPM mice. RESULTS: Compared with controls, in TASTPM mice PET image analysis demonstrated significantly increased (by a factor of ~1.3) brain concentration of (64)Cu at 30 min (P < 0.01) and 24 h (P < 0.05) after injection of the tracer and faster (by a factor of ~5) (64)Cu clearance from the brain (P < 0.01). Atlas-based quantification and texture analysis revealed significant differences in regional brain uptake of (64)Cu and PET image heterogeneity between the 2 groups of mice. Ex vivo autoradiography showed that regional brain distribution of (64)Cu at 24 h after injection did not correlate with amyloid-ß plaque distribution in TASTPM mice. CONCLUSION: The trafficking of (64)Cu in the brain after administration of (64)Cu-GTSM is significantly altered by AD-like pathology in the TASTPM mouse model, suggesting that (64)Cu-GTSM PET imaging warrants clinical evaluation as a diagnostic tool for AD and possibly other neurodegenerative disorders.


Subject(s)
Alzheimer Disease/diagnostic imaging , Alzheimer Disease/metabolism , Copper/metabolism , Positron-Emission Tomography , Animals , Autoradiography , Biological Transport , Brain/diagnostic imaging , Brain/metabolism , Copper Radioisotopes/chemistry , Copper Radioisotopes/pharmacokinetics , Disease Models, Animal , Mice , Solvents/chemistry , Tissue Distribution
5.
Eur J Nucl Med Mol Imaging ; 39(9): 1497-509, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22790877

ABSTRACT

Over the last decade, small-animal PET imaging has become a vital platform technology in cancer research. With the development of molecularly targeted therapies and drug combinations requiring evaluation of different schedules, the number of animals to be imaged within a PET experiment has increased. This paper describes experimental design requirements to reach statistical significance, based on the expected change in tracer uptake in treated animals as compared to the control group, the number of groups that will be imaged, and the expected intra-animal variability for a given tracer. We also review how high-throughput studies can be performed in dedicated small-animal PET, high-resolution clinical PET systems and planar positron imaging systems by imaging more than one animal simultaneously. Customized beds designed to image more than one animal in large-bore small-animal PET scanners are described. Physics issues related to the presence of several rodents within the field of view (i.e. deterioration of spatial resolution and sensitivity as the radial and the axial offsets increase, respectively, as well as a larger effect of attenuation and the number of scatter events), which can be assessed by using the NEMA NU 4 image quality phantom, are detailed.


Subject(s)
Motivation , Neoplasms/diagnostic imaging , Positron-Emission Tomography/methods , Research Design/statistics & numerical data , Animals , Humans , Image Processing, Computer-Assisted , Nuclear Medicine , Positron-Emission Tomography/instrumentation
6.
J Nucl Med ; 52(11): 1741-7, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21969357

ABSTRACT

UNLABELLED: The NanoPET/CT represents the latest generation of commercial preclinical PET/CT systems. This article presents a performance evaluation of the PET component of the system according to the National Electrical Manufacturers Association (NEMA) NU-4 2008 standard. METHODS: The NanoPET/CT consists of 12 lutetium yttrium orthosilicate:cerium modular detectors forming 1 ring, with 9.5-cm axial coverage and a 16-cm animal port. Each detector crystal is 1.12 × 1.12 × 13 mm, and 1 module contains 81 × 39 of these crystals. An optical light guide transmits the scintillation light to the flat-panel multianode position-sensitive photomultiplier tubes. Analog-to-digital converter cards and a field-programmable gate array-based data-collecting card provide the readout. Spatial resolution, sensitivity, counting rate capabilities, and image quality were evaluated in accordance with the NEMA NU-4 standard. Energy and temporal resolution measurements and a mouse imaging study were performed in addition to the standard. RESULTS: Energy resolution was 19% at 511 keV. The spatial resolution, measured as full width at half maximum on single-slice rebinning/filtered backprojection-reconstructed images, approached 1 mm on the axis and remained below 2.5 mm in the central 5-cm transaxial region both in the axial center and at one-quarter field of view. The maximum absolute sensitivity for a point source at the center of the field of view was 7.7%. The maximum noise equivalent counting rates were 430 kcps at 36 MBq and 130 kcps at 27 MBq for the mouse- and rat-sized phantoms, respectively. The uniformity and recovery coefficients were measured with the image-quality phantom, giving good-quality images. In a mouse study with an (18)F-labeled thyroid-specific tracer, the 2 lobes of the thyroid were clearly distinguishable, despite the small size of this organ. The flexible readout system allowed experiments to be performed in an efficient manner, and the system remained stable throughout. CONCLUSION: The large number of detector crystals, arranged with a fine pitch, results in excellent spatial resolution, which is the best reported for currently available commercial systems. The absolute sensitivity is high over the field of view. Combined with the excellent image quality, these features make the NanoPET/CT a powerful tool for preclinical research.


Subject(s)
Multimodal Imaging/instrumentation , Nanotechnology/instrumentation , Positron-Emission Tomography , Societies/standards , Tomography, X-Ray Computed , Animals , Female , Mice , Multimodal Imaging/standards , Nanotechnology/standards , Phantoms, Imaging , Rats , Reference Standards , Scattering, Radiation , Time Factors
8.
Opt Express ; 18(14): 14547-52, 2010 Jul 05.
Article in English | MEDLINE | ID: mdl-20639940

ABSTRACT

The polarization properties of light emitting diodes with integrated wire grid polarizers are investigated. Rigorous coupled wave analysis and Monte-Carlo ray tracing are used for modeling the gratings and the entire LED structure respectively. We show that it is more advantageous to place the polarizer onto the LED encapsulation rather than onto the die. With the proposed arrangement the average extinction ratio is 2.37 in the uncollimated case and 76.86 in the collimated case, while the light extraction efficiency is significantly higher than that of the LED + external polarizer combination. The achieved results compare favorably to other polarized LED solutions proposed in the literature.

9.
Eur J Nucl Med Mol Imaging ; 37(11): 2108-16, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20577737

ABSTRACT

PURPOSE: The human sodium/iodide symporter (hNIS) is a well-established target in thyroid disease and reporter gene imaging using gamma emitters (123)I-iodide, (131)I-iodide and (99m)Tc-pertechnetate. However, no PET imaging agent is routinely available. The aim of this study was to prepare and evaluate (18)F-labelled tetrafluoroborate ([(18)F]TFB) for PET imaging of hNIS. METHODS: [(18)F]TFB was prepared by isotopic exchange of BF (4) (-) with [(18)F]fluoride in hot hydrochloric acid and purified using an alumina column. Its identity, purity and stability in serum were determined by HPLC, thin-layer chromatography (TLC) and mass spectrometry. Its interaction with NIS was assessed in vitro using FRTL-5 rat thyroid cells, with and without stimulation by thyroid-stimulating hormone (TSH), in the presence and absence of perchlorate. Biodistribution and PET imaging studies were performed using BALB/c mice, with and without perchlorate inhibition. RESULTS: [(18)F]TFB was readily prepared with specific activity of 10 GBq/mg. It showed rapid accumulation in FRTL-5 cells that was stimulated by TSH and inhibited by perchlorate, and rapid specific accumulation in vivo in thyroid (SUV = 72 after 1 h) and stomach that was inhibited 95% by perchlorate. CONCLUSION: [(18)F]TFB is an easily prepared PET imaging agent for rodent NIS and should be evaluated for hNIS PET imaging in humans.


Subject(s)
Boric Acids/chemical synthesis , Genes, Reporter , Molecular Imaging/methods , Positron-Emission Tomography/methods , Symporters/genetics , Thyroid Diseases/diagnostic imaging , Animals , Borates , Boric Acids/metabolism , Boric Acids/pharmacokinetics , Cell Line , Drug Stability , Female , Fluorine Radioisotopes , Humans , Male , Mice , Rats , Symporters/metabolism , Thyroid Diseases/metabolism , Thyroid Gland/cytology , Thyroid Gland/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...